EGFR and non-small cell lung carcinoma: In patients with advanced NSCLC with EFGR mutations, the first generation of gefitinib and the third generation of osimertinib, which is effective against the resistance mutation EGFR T790M, limited the durability of the response and did not show the benefit of tail-plateau on progression-free survival curves [7, 8].